Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Authors: C. Lebbe, R. Bahleda, E. Ezine, B. Baroudjian, M. Sakkal, E. Rowinski, A. Vinceneux, S. Champiat, K. Bidet Huang, N. Stojkowitz, H. Makhloufi, A. Sadoun, A ...
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy ExpertsAntoine Italiano and Ignacio Melero Strasbourg, France, January 23, 2026, 8:00 a.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results